Bin Sun
Eli Lilly and Company
5 Papers
112 Citations
Bin Sun is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Insulin & Diabetes mellitus. The author has an hindex of 3, co-authored 4 publications.
Chat about Author
Papers
Improved postprandial blood glucose control and reduced nocturnal hypoglycemia during treatment with two novel insulin lispro-protamine formulations, insulin lispro Mix25 and insulin lispro Mix50
TL;DR: Compared with human insulin mixtures, twice-daily administration of insulin lispro mixtures resulted in improved postprandial glycemic control, similar overall glycemic Control, and less nocturnal hypoglycemia, as well as offering the convenience of dosing closer to meals.
81
Comparative efficacy of preprandial or postprandial humalog® mix75/25™ versus glyburide in patients 60 to 80 years of age with type 2 diabetes mellitus☆
Matthias Herz,Bin Sun,Zvonko Milicevic,Pamella Erickson,Jozsef Fövènyi,Marek Grzywa,Terezie Pelikanova +6 more
TL;DR: Compared with glyburide, Mix75/25 significantly improved gly glucose control in older patients with type 2 diabetes mellitus, could be administered after meals without compromising glycemic control, and was well tolerated.
33
Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Aspart (MYL-1601D) Compared with Originator Insulin Aspart (Novolog®) in Patients with Type 1 Diabetes After 24 Weeks: A Randomized Open-Label Study
Thomas Blevins,Yaron Raiter,Bin Sun,Charles Donnelly,Roxann Shapiro,Anoop Chullikana,Anita U. Rao,Laxmikant Vashishta,G. Ranganna,Abhijit Barve +9 more
TL;DR: In this article , the authors evaluated the immunogenicity, efficacy, and safety of MYL-1601D with Ref-InsAsp-US in patients with type 1 diabetes mellitus (T1D).
Basal-bolus insulin therapy in Type 1 diabetes: comparative study of pre-meal administration of a fixed mixture of insulin lispro (50%) and neutral protamine lispro (50%) with human soluble insulin.
TL;DR: To ascertain whether pre‐meal administration of 50% insulin lispro and 50% neutral protamine lisPro, given as a fixed mixture, provides satisfactory glycaemic control throughout the day compared with pre-meal human soluble (regular) insulin as a basal‐bolus regimen in people with Type 1 diabetes.